NCT06750276View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

July 28, 2025

Study Completion Date

July 28, 2025

Conditions
Liver FibrosisHepatic Cirrhosis
Interventions
DRUG

AZD2389

Doses of AZD2389 or placebo will be administered orally.

Trial Locations (9)

28557

Research Site, Morehead City

30349

Research Site, Atlanta

77079

Research Site, Houston

78215

Research Site, San Antonio

78229

Research Site, San Antonio

85224

Research Site, Chandler

92377

Research Site, Rialto

00927

Research Site, San Juan

CB2 0QQ

Research Site, Cambridge

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY